Promising New Cancer Therapy Developed by Albert Einstein College of Medicine
Whats New,
The image at left shows PVR, a tumor-cell protein, binding to the NK receptor KIR2DL5 in order to stop NK-cell attacks. The…
The image at left shows PVR, a tumor-cell protein, binding to the NK receptor KIR2DL5 in order to stop NK-cell attacks. The…
Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system's T cells to attack tumor cells.